News

THE BOARD OF DIRECTORS OF KARO PHARMA HAS RESOLVED ON A FULLY GUARANTEED RIGHTS ISSUE SUBJECT TO APPROVAL BY THE ANNUAL GENERAL MEETING

04 April, 2018

On 1 March 2018, Karo Pharma AB (”Karo Pharma” or the “Company”) announced the agreement to acquire a product portfolio from the Danish pharmaceutical company LEO Pharma A/S (the ”Acquisition”). The Acquisition is financed by a combination of new loans and a rights issue On 4 April 2018, the Board of Directors resolved on a...

Läs mer

KARO PHARMA SUPPORTS OPERATION SMILE

23 March, 2018

Karo Pharma has decided to support Operation Smile with a donation of 2,5 MSEK. The Chairman of Karo Pharma will make a private donation of the same amount. The total sum of 5 MSEK enables more than 2000 surgeries of children suffering from lip and cleft palate. In addition, the company has decided to donate...

Läs mer

KARO PHARMA ACQUIRES A MAJOR PRODUCT PORTFOLIO

01 March, 2018

· Karo Pharma acquires a product portfolio from the Danish pharmaceutical company LEO Pharma A/S for 260 MEURO, effective from 4th of April 2018. · The turnover of the acquired product portfolio was ca 700 MSEK in 2017. Half of the turnover comes from the Nordics, ca 266 MSEK from the rest of Europe and...

Läs mer

CHANGE IN THE NUMBER OF SHARES AND VOTES IN KARO PHARMA

31 January, 2018

STOCKHOLM 31 January 2018 – As of 31 January 2018, the last trading day of the month, the aggregate number of shares and votes in Karo Pharma AB amounts to 109,555,188. The increase in the number of shares and votes is attributable to the recently completed rights issue of 27,388,797 shares. The rights issue was...

Läs mer